Xenon Pharmaceuticals Inc. (XENE)Healthcare | Biotechnology | Burnaby, Canada | NasdaqGM
67.72 USD
-1.20
(-1.741%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 5:40 a.m. EDT
The immediate outlook is driven by a powerful convergence of positive clinical catalysts and aggressive speculative positioning. Recent headlines regarding epilepsy trial progress and a 40% surge on data suggest the market is re-rating the company's core assets, while the options chain confirms this with a distinct bullish bias where traders are betting on a move toward the $75-$80 range. However, this optimism sits atop a precarious fundamental foundation: the company is burning significant cash with negative free cash flow and no revenue, resulting in a negative forward P/E. While the balance sheet currently appears robust relative to debt, the lack of commercial traction means this is purely a binary event-driven play. The long-term investment case remains neutral due to the absence of a proven revenue engine and the inherent risks of late-stage biotech development, making this a high-risk, high-reward trade dependent on upcoming data readouts rather than a sustainable business model. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.033163 |
| AutoARIMA | 0.033395 |
| MSTL | 0.034558 |
| AutoTheta | 0.071705 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 2.80 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.227 |
| Excess Kurtosis | -0.13 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.56 |
| Market Cap | 6,546,191,360 |
| Forward P/E | -13.52 |
| Beta | 0.61 |
| Website | https://www.xenon-pharma.com |
As of July 11, 2026, 5:40 a.m. EDT: Speculators are aggressively positioning for upside, evidenced by heavy open interest concentration in out-of-the-money calls at strikes 75 and 80 for near-term expirations. The call volume-to-open-interest ratio is significantly elevated at the 75 strike, indicating active buying rather than passive hedging. Conversely, put activity is sparse and concentrated deep in-the-money, suggesting limited defensive positioning compared to the bullish call skew. Implied volatility remains elevated for near-term strikes, pricing in continued uncertainty around clinical milestones.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.1141105 |
| Address1 | 200-3650 Gilmore Way |
| All Time High | 72.66 |
| All Time Low | 2.1 |
| Ask | 84.99 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Daily Volume10 Day | 2,658,000 |
| Average Daily Volume3 Month | 1,423,314 |
| Average Volume | 1,423,314 |
| Average Volume10Days | 2,658,000 |
| Beta | 0.613 |
| Bid | 47.88 |
| Bid Size | 2 |
| Board Risk | 1 |
| Book Value | 7.271 |
| City | Burnaby |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | Canada |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 67.72 |
| Current Ratio | 27.794 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 67.87 |
| Day Low | 65.5301 |
| Debt To Equity | 0.56 |
| Display Name | Xenon Pharmaceuticals |
| Earnings Call Timestamp End | 1,778,185,800 |
| Earnings Call Timestamp Start | 1,778,185,800 |
| Earnings Timestamp | 1,778,184,000 |
| Earnings Timestamp End | 1,778,184,000 |
| Earnings Timestamp Start | 1,778,184,000 |
| Ebitda | -410,188,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -13.308 |
| Enterprise Value | 5,458,935,296 |
| Eps Current Year | -4.81031 |
| Eps Forward | -5.00938 |
| Eps Trailing Twelve Months | -4.7 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 56.205 |
| Fifty Day Average Change | 11.514999 |
| Fifty Day Average Change Percent | 0.20487499 |
| Fifty Two Week Change Percent | 111.41105 |
| Fifty Two Week High | 72.66 |
| Fifty Two Week High Change | -4.9400024 |
| Fifty Two Week High Change Percent | -0.06798792 |
| Fifty Two Week Low | 30.0 |
| Fifty Two Week Low Change | 37.72 |
| Fifty Two Week Low Change Percent | 1.2573334 |
| Fifty Two Week Range | 30.0 - 72.66 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,415,197,800,000 |
| Float Shares | 90,758,318 |
| Forward Eps | -5.00938 |
| Forward P E | -13.51864 |
| Free Cashflow | -186,274,496 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 358 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Gross Profits | -328,246,016 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00125 |
| Held Percent Institutions | 1.07512 |
| Implied Shares Outstanding | 96,665,550 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. |
| Long Name | Xenon Pharmaceuticals Inc. |
| Market | us_market |
| Market Cap | 6,546,191,360 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_565718 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -383,164,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 6,662,189,706 |
| Number Of Analyst Opinions | 19 |
| Open | 67.79 |
| Operating Cashflow | -306,363,008 |
| Operating Margins | 0.0 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Phone | 604 484 3300 |
| Pre Market Change | 0.12999725 |
| Pre Market Change Percent | 0.19196287 |
| Pre Market Price | 67.85 |
| Pre Market Time | 1,784,023,130 |
| Previous Close | 68.92 |
| Price Eps Current Year | -14.078095 |
| Price Hint | 2 |
| Price To Book | 9.313712 |
| Price To Sales Trailing12 Months | Infinity |
| Profit Margins | 0.0 |
| Quick Ratio | 27.525 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -1.2 |
| Regular Market Change Percent | -1.74114 |
| Regular Market Day High | 67.87 |
| Regular Market Day Low | 65.5301 |
| Regular Market Day Range | 65.5301 - 67.87 |
| Regular Market Open | 67.79 |
| Regular Market Previous Close | 68.92 |
| Regular Market Price | 67.72 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 1,527,396 |
| Return On Assets | -0.24215999 |
| Return On Equity | -0.37533 |
| Revenue Per Share | 0.0 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 96,665,550 |
| Shares Percent Shares Out | 0.0647 |
| Shares Short | 6,257,737 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 4,044,948 |
| Short Name | Xenon Pharmaceuticals Inc. |
| Short Percent Of Float | 0.0648 |
| Short Ratio | 3.56 |
| Source Interval | 15 |
| State | BC |
| Symbol | XENE |
| Target High Price | 100.0 |
| Target Low Price | 63.0 |
| Target Mean Price | 80.56053 |
| Target Median Price | 80.0 |
| Total Cash | 1,094,747,008 |
| Total Cash Per Share | 11.325 |
| Total Debt | 7,491,000 |
| Total Revenue | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.7 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 48.117523 |
| Two Hundred Day Average Change | 19.602478 |
| Two Hundred Day Average Change Percent | 0.40738752 |
| Type Disp | Equity |
| Volume | 1,527,396 |
| Website | https://www.xenon-pharma.com |
| Zip | V5G 4W8 |